Triamcinolone acetonide

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

Retrieved on: 
Thursday, September 7, 2023
HTN, AE, Lidocaine, OAK, Oxycodone, Aes, Clinical trial, ECG, Capsaicin, Bankruptcy, Female, Pain, Hypertension, SPID, SAE, Patient, Standard of care, WOMAC, KOOS, SAN, OTC, Hydromorphone, BMI, FDA, Therapy, Triamcinolone acetonide, RTX, Safety, Pharmaceutical industry, Birth control

RTX 20mcg and 12.5mcg have been selected as the clinically optimal and minimally effective doses for further phase 2 pivotal or phase 3 trials.

Key Points: 
  • RTX 20mcg and 12.5mcg have been selected as the clinically optimal and minimally effective doses for further phase 2 pivotal or phase 3 trials.
  • SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") announced today positive Phase 2a top-line clinical trial results for the RTX program.
  • A higher proportion of patients responded to treatment with RTX 20mcg than any other treatment group, including Zilretta.
  • The clinical trial confirmed the potential of resiniferatoxin (RTX) in helping patients with moderate to severe osteoarthritis pain for at least 6 months, if not longer.

Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)

Retrieved on: 
Monday, August 9, 2021
Plasma, Technology, Anaphylaxis, U.S. Securities and Exchange Commission, Bruise, AES, Knee, Synovial fluid, Intrathecal administration, Intellectual property, Incidence, Osteoarthritis, GLOBE, COVID-19, TA, FDA, Septic arthritis, Triamcinolone, OA, Therapy, Arthritis, Shoulder, Nasdaq, Sinusitis, Arthralgia, Pain, Triamcinolone acetonide, Risk, Patient, SEC, Flexion Therapeutics, PK, PLGA, Safety, Cough, Fever, Security (finance), Epidural administration, Pharmaceutical industry, Vaccine

The study compared the plasma PK profile of ZILRETTA to immediate-release triamcinolone acetonide in crystalline suspension (TAcs) and assessed the safety and general tolerability of ZILRETTA in osteoarthritis (OA) of the shoulder.

Key Points: 
  • The study compared the plasma PK profile of ZILRETTA to immediate-release triamcinolone acetonide in crystalline suspension (TAcs) and assessed the safety and general tolerability of ZILRETTA in osteoarthritis (OA) of the shoulder.
  • In the Phase 2, randomized, open-label, single-dose study, 25 adults with moderate to severe shoulder OA received a single ultrasound-guided intra-articular (IA) injection of either ZILRETTA (n=12) or TAcs (n=13).
  • PK and safety profiles of ZILRETTA were similar to those reported in Phase 3 studies of patients with knee OA.
  • Flexion plans to initiate a registration trial to further investigate ZILRETTA in shoulder OA later this year.

Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, August 4, 2021
Steroids, Chemical compounds, Chemistry, Flexion Therapeutics, Acetonides, Diketones, Glucocorticoids, Pregnanes, Triamcinolone acetonide

ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2million in Q2 2021, reflecting growth of 15% over the previous quarter

Key Points: 
  • ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2million in Q2 2021, reflecting growth of 15% over the previous quarter
    Net loss in Q2 2021 decreased by $10.4million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA sales
    BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June30, 2021.
  • Net sales of ZILRETTA were $28.2million and $15.5million for the three months ended June30, 2021 and 2020, respectively.
  • Loss per share for the second quarter of 2021 was $0.44, compared to $0.76 for the same period of 2020.
  • Research and development expenses were $12.7million and $12.5million for the three months ended June30, 2021 and 2020, respectively.

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

Retrieved on: 
Monday, February 8, 2021
Glucocorticoids, Organofluorides, Medicine, Chemistry, Chemical compounds, Pregnanes, Acetonides, Diketones, Macular edema, Triamcinolone acetonide, Uveitis, Macula of retina

Favorable results from preclinical studies of a triamcinolone acetonide suspension translated to favorable clinical trial results for macular edema associated with non-infectious uveitis.

Key Points: 
  • Favorable results from preclinical studies of a triamcinolone acetonide suspension translated to favorable clinical trial results for macular edema associated with non-infectious uveitis.
  • In this analysis, 93,756 patient eyes were assessed from de-identified medical records from hundreds of retina specialists across the United States.
  • These forward-looking statements include statements regarding the clinical development and the potential benefits of CLS-TA and therapies using Clearsides SCS Microinjector.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million

Retrieved on: 
Tuesday, October 13, 2020
RTT, Medical specialties, Steroids, Glucocorticoids, Acetonides, Organofluorides, Chemical compounds, Rheumatology, Flexion Therapeutics, Triamcinolone acetonide, Triamcinolone, Joint injection

BURLINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA(triamcinolone acetonide extended-release injectable suspension) net sales of $23.6 million for the quarter ended September 30, 2020.

Key Points: 
  • BURLINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA(triamcinolone acetonide extended-release injectable suspension) net sales of $23.6 million for the quarter ended September 30, 2020.
  • Each year, healthcare providers administer approximately eight million intra-articular injections to help patients manage osteoarthritis knee pain.
  • 77% of purchasing accounts (3,153) placed at least one reorder up from 2,983 accounts that had reordered ZILRETTA as of June 30, 2020.
  • Accounts that had purchased more than 50 ZILRETTA units accounted for 258,562 of the total 295,641 ZILRETTA units purchased.

Flexion Therapeutics to Host Physician Event at Orthopaedic Summit 2019 Featuring Panel of Former Professional Athletes Treated With ZILRETTA® for Osteoarthritis Knee Pain

Retrieved on: 
Monday, December 9, 2019
Medical specialties, Musculoskeletal system, RTT, Medicine, Rheumatology, Skeletal disorders, Glucocorticoids, Organofluorides, Joint injection, Osteoarthritis, Triamcinolone acetonide, Hyaluronic acid

Dr. Richmond will kick off the program with a review of the clinical data supporting ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an intra-articular treatment for osteoarthritis knee pain.

Key Points: 
  • Dr. Richmond will kick off the program with a review of the clinical data supporting ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an intra-articular treatment for osteoarthritis knee pain.
  • Dr. Hanson will then join Knee to Knee, a dynamic panel discussion including retired professional athletes and moderated by NFL player turned broadcaster Solomon Wilcots .
  • Indication: ZILRETTA is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.
  • Each year, approximately five million OA patients receive either an immediate-release corticosteroid or hyaluronic acid intra-articular injection to manage their knee pain.

Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings

Retrieved on: 
Monday, November 11, 2019
Organic compounds, Chemical compounds, Chemistry, Glucocorticoids, Acetonides, Organofluorides, RTT, Corticosteroids, Triamcinolone acetonide, Osteoarthritis, Joint injection, Triamcinolone

The findings suggest that pre-treatment concordance across two pain assays may serve as an important patient eligibility criterion in future clinical trials.

Key Points: 
  • The findings suggest that pre-treatment concordance across two pain assays may serve as an important patient eligibility criterion in future clinical trials.
  • The data was presented in a poster session (Poster: 285) on November 8 at the recent American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting.
  • Indication: ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.
  • Contraindication: ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product.

Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®

Retrieved on: 
Monday, October 14, 2019
Organic compounds, Glucocorticoids, Organofluorides, RTT, Chemistry, Chemical compounds, Flexion Therapeutics, Triamcinolone acetonide, Food and Drug Administration, Joint injection, Osteoarthritis, Triamcinolone

BURLINGTON, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA)has informed the company it needs additional time to complete the review of the supplemental New Drug Application (sNDA) for ZILRETTA (triamcinolone acetonide extended-release injectable suspension).

Key Points: 
  • BURLINGTON, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA)has informed the company it needs additional time to complete the review of the supplemental New Drug Application (sNDA) for ZILRETTA (triamcinolone acetonide extended-release injectable suspension).
  • Although the FDA did not provide a new action date, the FDA informed the company that the review is expected to be completed in the coming weeks.
  • The FDA has not asked for any additional clinical data and the company has provided the FDA with all information requested to date.
  • Indication: ZILRETTA is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.